Pharmaceuticals

Sai Life Sciences' plan to hire 700+ professionals underscores a global shift, positioning India as a critical hub for pharmaceutical R&D and manufacturing.

MAIA Pharmaceuticals will bring Teribone™, a proven therapy used in Japan, to the US, aiming to solve the critical patient adherence crisis in osteoporosis care.

Pharma giant AbbVie raises its dividend, backed by robust financials and a powerful drug pipeline that signals a thriving post-Humira growth era.

Klothea Bio's trial for a 'longevity protein' drug in Honduras pushes the boundaries of science, but raises questions about offshore research and equity.

Innoviva prepares for a key investor conference, spotlighting its shift to specialty drugs and navigating questions on its diversified growth strategy.

Reunion Neuroscience hits the investor conference circuit, seeking capital to advance its groundbreaking psychedelic-inspired therapies for depression and anxiety.

With new kits for complex cell models, Atrandi's semi-permeable capsules challenge market leaders by enabling multi-step workflows previously out of reach.

With a major €12.5M EU funding package, Step Pharma is fast-tracking dencatistat, a novel therapy targeting a key vulnerability in ovarian and endometrial cancers.

New data shows an AI-driven approach is enrolling IBD patients 3.4x faster, promising to accelerate the delivery of novel therapies to those in need.

Amid regional conflict, InterCure reports NIS 265M revenue, enters German market, and makes strategic US moves, showcasing remarkable resilience and growth.

Serina Therapeutics enrolls the first patient in a trial for SER-252, a novel Parkinson's therapy designed to improve symptoms without current side effects.

With major grants from top foundations, Lario Therapeutics expands its precision neuroscience platform, offering new hope for complex neurological disorders.

Early data reveals a novel immunotherapy, STC-1010, may activate the immune system against a common, treatment-resistant form of colorectal cancer.

As argenx prepares its full-year 2025 update, investors are watching if the VYVGART sales boom can fund a pipeline aimed at dominating autoimmune care.

With its CEO and CFO set for key conferences, Aptar will address investors following a strong sales quarter but facing questions on profitability.

With impressive preliminary sales and key pipeline updates, Mirum Pharmaceuticals' upcoming earnings call will focus on its strategy for sustained growth in 2026.

A groundbreaking, NIH-funded trial will use advanced PET imaging to test new Alzheimer's drugs, with XingImaging managing the critical visual data.

Johnson & Johnson is investing over $1 billion in a new Pennsylvania cell therapy hub, promising revolutionary treatments and thousands of new jobs.

Flatiron Health launches a first-of-its-kind AI platform, merging data from 400,000 patients to revolutionize prostate cancer research and treatment.

Olympia Pharmaceuticals unveils Circulate, a single-dose IV premix blending science and efficiency to support vascular health and streamline clinic operations.